|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Background:</b> Diabetic nephropathy (DN) is the leading cause of end-stage failure of the kidneys; however, its pathogenesis remains unknown.
|
31338070 |
2019 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
88.7% for moderate-to-severe DKD) of patients predicted to be at high-risk of MACRO did not have diabetic nephropathy, proteinuria, or CKD at baseline.<b>Conclusions:</b> The models developed using insurance claims data could reliably predict the risk of MACRO in patients with T2DM and enabled patients at higher-risk of DKD to be identified in the absence of baseline diabetic nephropathy, CKD, or proteinuria.
|
31625766 |
2020 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diabetic nephropathy (DN) is the leading cause of end-stage renal disease.
|
16813599 |
2006 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diabetic nephropathy (DN) was categorized by urinary albumin excretion (UAE) as normoalbuminuria (n=247), microalbuminuria (n=68), macroalbuminuria (n=70), or the presence of end-stage renal disease (dialysis; n=134).
|
20097100 |
2011 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diabetic nephropathy (DN) is the most common cause of end-stage renal disease and identification of new therapeutic targets is needed.
|
24287278 |
2014 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diabetic nephropathy (DN) is a major cause of end stage kidney disease and a strong risk factor for cardiovascular diseases.
|
24361893 |
2014 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diabetic nephropathy (DN) is a major microvascular complication that develops in nearly 20-30% of patients with type 2 diabetes (T2D) and is currently the leading cause of end stage renal disease (ESRD).
|
25154422 |
2015 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diabetic nephropathy (DN) is the second most frequent and prevalent complication of diabetes mellitus (DM).
|
29808088 |
2018 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diabetic nephropathy (DN) is one of the most devastating complications of diabetes mellitus.
|
30420491 |
2018 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diabetic nephropathy (DN) is a major complication in diabetic patients.
|
30486327 |
2018 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diabetic nephropathy (DN) occurrence in transplanted kidneys is poorly investigated.
|
30526503 |
2018 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diabetic nephropathy (DN) has become the major complication of diabetes.
|
30575943 |
2018 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diabetic nephropathy (DN) is a primary cause of renal failure.
|
30761531 |
2019 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diabetic nephropathy (DN) is characterized by inflammation of renal tissue.
|
30784180 |
2019 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diabetic nephropathy (DN) is serious diabetic complication with capillary injury.
|
30834596 |
2019 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diabetic nephropathy (DN) is a major complication of diabetes.
|
30867431 |
2019 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diabetic Nephropathy (DN) is the most common cause of end-stage renal disease associated with high mortality worldwide.
|
31188032 |
2019 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diabetic nephropathy (DN) is one of the most serious chronic complications of diabetes mellitus (DM).
|
31359358 |
2019 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diabetic nephropathy (DN) was induced in male C57BL/6 mice by the injection of streptozotocin (STZ, 50 mg kg<sup>-1</sup>) in citrate buffer on 5 consecutive days.
|
31363726 |
2019 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diabetic nephropathy (DN) affects about 40% of diabetes mellitus (DM) patients and is the leading cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) all over the world, especially in high- and middle-income countries.
|
31409386 |
2019 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diabetic nephropathy (DN) is the leading cause of end-stage renal disease worldwide with high morbidity and mortality.
|
31410160 |
2019 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diabetic nephropathy (DN) is a major complication of diabetes.
|
31601446 |
2019 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diabetic nephropathy (dNP), a leading cause of end-stage renal disease in industrialized countries, is mechanistically closely linked with ER stress and renal cell death.
|
31701452 |
2020 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diabetic nephropathy (DN) is a major microvascular complication of diabetes.
|
31827549 |
2019 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation and Study of Diabetic Nephropathy with Atrasentan: what was learned about the treatment of diabetic kidney disease with canagliflozin and atrasentan?
|
31198532 |
2019 |